Biocon Limited — Updates, 12-02-2026: General Updates
12-02-2026 | 07:28 pm
12-02-2026 | 07:28 pm
Biocon reported Q3 results with consolidated revenue at ₹4,173 Cr. A net loss of ₹51.8 Cr occurred due to one-off expenses. The Board also granted in-principle approval to acquire the remaining ~2% of Biocon Biologics via preferential share allotment, making it a wholly-owned subsidiary.
No comments yet. Be the first to comment!
